Product Description
Cediranib is a potent small molecule vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK) inhibitor of all three VEGF receptors (VEGFR-1, 2 and 3) at nanomolar concentrations. (Sourced from: https://nciformulary.cancer.gov/available_agents/Cediranib.htm)
Mechanisms of Action: VEGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Canada, France, Germany, Israel, Puerto Rico, South Korea, Spain, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Carcinosarcoma|Clear Cell Adenocarcinoma|Colorectal Cancer|Endometrial Cancer|Endometrioid Carcinoma|Leiomyosarcoma|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma|Transitional Cell Carcinoma|Uveal Melanoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03851614 |
DAPPER | P2 |
Active, not recruiting |
Pancreatic Cancer|Leiomyosarcoma|Adenocarcinoma|Colorectal Cancer |
2027-01-01 |
12% |
2026-02-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT03660826 |
NCI-2017-01672 | P2 |
Active, not recruiting |
Endometrioid Carcinoma|Endometrial Cancer|Adenocarcinoma|Carcinosarcoma |
2024-12-06 |
2025-10-10 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT03334617 |
HUDSON | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2024-09-13 |
12% |
2025-10-28 |
|
2019-001045-40 |
CEDUVEAL-M | P2 |
Active, not recruiting |
Uveal Melanoma |
2023-03-02 |
2022-03-13 |
Treatments |
|
NCT04739800 |
NCI-2021-00615 | P2 |
Active, not recruiting |
Clear Cell Adenocarcinoma|Ovarian Cancer|Transitional Cell Carcinoma|Peritoneal Cancer|Endometrioid Carcinoma|Mucinous Cystadenocarcinoma|Mucinous Adenocarcinoma|Serous Cystadenocarcinoma |
2023-01-26 |
2024-11-27 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/28/2020 |
News Article |
ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer |
|
10/12/2020 |
News Article |
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma |
|
09/18/2020 |
News Article |
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers |
|
05/13/2020 |
News Article |
AstraZeneca Advances the Science of Cancer Medicine With Practice-Changing Data at the ASCO20 Virtual Scientific Program |